Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2005

01-09-2005 | Review

Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?

Authors: Ronald de Wit, Matti Aapro, Peter R Blower

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2005

Login to get access

Abstract

5-HT3-receptor antagonists are the current antiemetic ‘gold standard’ for chemotherapy- and radiotherapy-induced nausea and vomiting. Interestingly, studies have shown that patients experiencing poor control of acute chemotherapy-induced nausea and vomiting with one antiemetic therapy may respond well to another agent, including a drug of the same class. This review examines pharmacological differences between the 5-HT3-receptor antagonists in order to determine potential reasons for their differing efficacy, particularly in relation to refractory emesis. Differences in drug metabolism by the cytochrome P450 system, inadequate dosing of the respective agents, differences in onset and duration of action, and effects on serotonin release and reuptake are discussed.
Literature
1.
ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery (1999). Am J Health Syst Pharm 56:729–764
2.
Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR et al (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969–1975
3.
Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557–566
4.
Blower P, Aapro M (2002) Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? Br J Cancer 86:1665–1666
5.
Blower PR (2002) 5-HT3-receptor antagonist and the cytochrome P450 system: clinical implications. Cancer J 8:405–414
6.
Bosnjak SM, Neskovic-Konstantinovic ZB, Jovanovic-Micic DJ, Mitrovic LB, Radulovic SS (1996) Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. J Chemother 8:315–318
7.
Bruntsch U, Rufenacht E, Parker I, Drechsler S, de Bruijn K (1993) Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy. Ann Oncol 4(Suppl 3):25–29
8.
Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R (2002) Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123:425–432
9.
Camilleri M, Mayer EA, Drossman DA, Heaths A, Dukes GE, McSorleys D, Kong S, Mangel AW, Northcutt AR (1999) Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13:1149–1159
10.
Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE (1998) Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs 9:381–385
11.
Castejon AM, Paez X, Hernandez L, Cubeddu LX (1999) Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther 291:960–966
12.
Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810–816
13.
Davis MP, Homsi J (2001) The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 9:442–451
14.
de Wit R (2003) Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer 88:1823–1827
15.
de Wit R, de Boer AC, Linden GHM, Stoter G, Sparreboom A, Verweij J (2001) Effective crossover to granisetron after failure to ondansetron, a randomized double-blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 85:1099–1101
16.
Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225–1230
17.
Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Onc Nurs 3:113–119
18.
Endo T, Hamaue N, Ihira E, Teramoto Y, Liu Y, Hirafuji M, Minami M (2002) Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model. Res Commun Mol Pathol Pharmacol 111:55–68
19.
Endo T, Minami M, Hirafuji M, Ogawa T, Akita K, Nemoto M, Saito H, Yoshioka M, Parvez SH (2000) Neurochemistry and neuropharmacology of emesis–the role of serotonin. Toxicology 153:189–201
20.
Endo T, Minami M, Kitamura N, Teramoto Y, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yasuda E, Blower PR (1999) Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum. Res Commun Mol Pathol Pharmacol 104:145–153
21.
Endo T, Ogawa T, Hamaue N, Akita K, Hirafuji M, Minami M, Blower PR (1998) Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets. Res Commun Mol Pathol Pharmacol 100:243–253
22.
Endo T, Takahashi M, Minami M, Yoshioka M, Saito H, Parvez SH (1993) Effects of anticancer drugs on enzyme activities and serotonin release from ileal tissue in ferrets. Biol Amines 9:479–489
23.
Farley PA, Shillington AC, Dempsey CL, Colgan K (2003) 5-HT3 antiemetic use in breast cancer patients receiving cyclophosphamide: a multicenter practice evaluation. Support Care Cancer 11:392 (Abstract A-20)
24.
Feyer P (2002) Nausea und emesis in der Strahlntherapie. Im Focus Onkologie 8:64–68
25.
Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ (1998) Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer 6:237–243
26.
Gebauer A, Merger M, Kilbinger H (1993) Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 347:137–140
27.
Gershon MD (2003) Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 3(Suppl 2):S25–S34
28.
Gershon MD, Ross LL (1966) Radioisotopic studies of the binding, exchange, and distribution of 5-hydroxytryptamine synthesized from its radioactive precursor. J Physiol 186:451–476
29.
Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C (1998) Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 16:1568–1573
30.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994
31.
Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 29:1074–1080
32.
Ihbe-Heffinger A, Kuhn W, Sattler D, Thödtmann J, Graeff, Bernard R (2000) Cost-minimization analysis for the use of 5-HT3-receptor antagonists in moderately emetogenic chemotherapy. A prospective pharmacoeconomic evaluation in German hospitals. Eur J Cancer 36:Abstract PP30
33.
Inoue T, Kusumi I, Yoshioka M (2002) Serotonin transporters. Curr Drug Target CNS Neurol Disord 1:519–529
34.
Italian Group for Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805–810
35.
Jann MW, Cohen LJ (2000) Ethnicity and antidepressant pharmacogenetics. Drug Metabol Drug Interact 16:39–67
36.
Jantunen IT, Muhononen TT, Kataja VV, Flander MK, Teerenhovi L (1993) 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. Eur J Cancer 29A:1669–1672
37.
Jordan K, Hinke A, Grothey A, Schmoll H-J (2003) A meta-analysis comparing the available 5-HT3-receptor antagonists as prophylactic agents for acute chemotherapy-induced emesis. Support Care Cancer 11:394 (Abstract A-29)
38.
Jordan K, Hinke A, Grothey A, Schmoll H-J (2004) A meta-analysis comparing the efficacy of five 5-HT3-receptor antagonists (5-HT3-RAs) for acute chemotherapy-induced emesis. Proc Am Soc Clin Oncol 23:737(Abstract 8048)
39.
Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811
40.
Krengli M, Lazzari R, Manara M (1996) The use of granisetron per os in radiotherapy-induced emesis. Minerva Med 87:605–608
41.
Leslie RA, Reynolds DJM (1993) Neurotransmitters and receptors in the emetic pathway. In: Andrews PLR, Sanger GJ (eds) Emesis in anti-cancer treatment: mechanisms and treatment. Chapman& Hall Medical, London, pp 91–112
42.
Lindley C, Blower P (2000) Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm 57:1685–1697
43.
MASCC (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819
44.
Massidda B, Ionta MT (1996) Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor antagonist in moderately emetogenic chemotherapy. J Chemother 8:237–242
45.
Minami M, Endo T, Nemoto M, Hamaue N, Hirafuji M, Monama Y, Yajima, Yoshioka M, Saitoh H (1995) How do toxic emetic stimuli cause 5-HT release in the gut and brain? In: Raynolds DJM (ed) Serotonin and the scientific basis of antiemetic therapy. Oxford Clinical Communications, Oxford, pp 68–76
46.
Minton NA (1994) Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists. Br J Clin Pharmacol 37:525–530
47.
Mitchell PL, Evans BD, Allan SG, Forgeson GV, Mak D, Neave L, Humm G, Langley G, Dickson D, Harvey VJ (1992) Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. N Z Med J 105:73–75
48.
Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204–2210
49.
Newberry N, Watkins C, Sprosen T, Blackburn T, Grahame-Smith D, Leslie R (1993) BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 32:729–735
50.
Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W (2002) Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin’s lymphoma. J Med Assoc Thai 85:1156–1163
51.
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754–760
52.
Roila F (1996) Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research. Oncology 53:65–7252
53.
Roila F, Del Favero A (1995) Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 29:95–109
54.
Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 51:113–118
55.
Schnell FM (2003) Chemotherapy-induced nausea and vomiting–the importance of acute antiemetic control. Oncologist 8:187–198
56.
Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 66:192–197
57.
Terrey J-P, Aapro MS (1996) The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res 8:281–288
58.
Tsavaris N, Kosmas CH, Vadiaka M, Kontos A, Katsorida M, Dimitrakopoulos A, Zerai A, Koufos CH (2001) Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. J Exp Clin Cancer Res 20:29–34
59.
Yalçin S, Tekuzman G, Baltali E, Özişik Y, Barişta I (1999) Serotonin antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy. A randomized study. Am J Clin Oncol 22:94–96
Metadata
Title
Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
Authors
Ronald de Wit
Matti Aapro
Peter R Blower
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-1033-0

Other articles of this Issue 3/2005

Cancer Chemotherapy and Pharmacology 3/2005 Go to the issue

Original Article

Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives

Original Article

Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models

Original Article

P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing

Short Communication

Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay

Original Article

Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo

Original Article

Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits